カテゴリ： GlobalData, アメリカ, 企業調査

Innovus Pharmaceuticals Inc (INNV)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Innovus Pharmaceuticals Inc (INNV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8243
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：99
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Innovus Pharmaceuticals Inc (Innovus Pharmaceuticals) is a pharmaceutical company that commercializes, licenses and develops over the counter and consumer healthcare products. The company’s products include non-drowsy allergy relief tablets, male fertility dietary supplements, blood sugar support supplement, weight loss supplement, lean gren bean coffee extract supplement, and others. Innovus Pharmaceuticals’ products are used in the areas of men’s and women’s health, vitality, sexual and reproductive health, pain, vision and respiratory disease. The company caters its products to urologists, primary care physicians, gynecologists, therapists and directly to consumers through on-line channels, retailers and wholesalers. Innovus Pharmaceuticals is headquartered in San Diego, California, the US.

Innovus Pharmaceuticals Inc (INNV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Innovus Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Innovus Pharma Acquires Assets of Beyond Human for USD0.6 Million 17
Innovus Pharma Acquires Vesele from Trophikos 18
Innovus Pharma Amends Acquisition of Rights to Circumserum from Centric Research for up to USD7.5 Million 19
Innovus Pharma To Acquire Prescription Product Portfolio From Prospector Capital Partners II 20
Venture Financing 22
Innovus Pharma Raises US$0.33 Million In Venture Financing 22
Innovus Pharma To Raise US$1.1 Million In Venture Financing 23
Partnerships 24
Innovus Pharma Enters into Distribution Agreement with Laboratorios Q Pharma 24
Innovus Pharma Enters into Co-Marketing Agreement with DanaLife for Zestra 25
Innovus Pharma Enters Into Co-Promotion Agreement With Consortia Health For EjectDelay 26
Licensing Agreements 27
Innovus Pharma Enters into License and Distribution Agreement with Lavasta Pharma 27
Corporacion Pharma Solutions Peru Enters into Licensing Agreement with Innovus Pharma 28
Innovus Pharma Plans to Enter into Licensing Agreement with University of Iowa Research Foundation 29
Luminarie Enters into Licensing Agreement with Innovus Pharma 30
Innovus Pharma Expands Licensing Agreement with Densmore for Zestra 31
Innovus Pharma Enters into Licensing Agreement with NTC 32
Innovus Pharma Enters into Licensing Agreement with J&H Co. for Zestra 33
Elis Pharma Enters into Licensing Agreement with Innovus Pharma for Zestra 34
Innovus Pharma Enters into Licensing Agreement with Seipel 35
Innovus Pharma Enters into Licensing Agreement with BroadMed for EjectDelay 36
Bio Task Enters into Licensing Agreement with Innovus Pharma 37
Khandelwal Labs Enters into Licensing Agreement with Innovus Pharma 38
Elis Pharma Enters into Licensing Agreement with Innovus Pharma 39
BroadMed Enters into Licensing Agreement with Innovus Pharma for Sensum+ 40
Innovus Pharma Enters into Licensing Agreement with Tabuk Pharma 41
Innovus Pharma Enters into Licensing Agreement with Sothema Labs 42
Innovus Pharma Enters into Licensing Agreement with Tramorgan for Sensum+ 43
Orimed Pharma Expands Licensing Agreement with Innovus Pharma 44
Innovus Pharma Enters Into Licensing Agreement With Ovation Pharma For EjectDelay 45
Innovus Pharma Enters Into License And Distribution Agreement With Ovation Pharma For Circumserum 46
Acerus Pharma Enters into Licensing and Distribution Agreement with Innovus Pharma 47
Equity Offering 48
Innovus Pharma Raises Funds through Private Placement 48
Innovus Pharma Prices Public Offering of Shares for USD3.9 Million 49
Innovus Pharma Files Registration Statement for Public Offering of Shares and Warrants for up to USD5 Million 50
Innovus Pharma to Raise Funds in Public Offering of Shares 51
Innovus Pharma to Raise USD0.2 Million in Private Placement of Shares upon Exercise of Warrants 52
Innovus Pharma Completes Private Placement Of Shares For US$0.13 Million 53
Innovus Pharma Completes Private Placement Of Shares For US$0.45 Million 54
Innovus Pharma Completes Private Placement Of Shares For US$4.5 Million 55
Debt Offering 56
Innovus Pharma Raises USD0.8 Million in Third and Final Tranche of Private Placement of 10% Notes Due 2017 56
Innovus Pharma Raises Additional USD0.75 Million in Private Placement of 10% Note Due 2017 57
Innovus Pharma Raises USD1.5 Million in Private Placement of 10% Note Due 2017 58
Innovus Pharmaceuticals Raises USD0.024 Million in Debt Offering of 10% Non-Convertible Debentures 59
Innovus Pharma Raises USD0.5 Million in Private Placement of 5% Notes Due 2016 60
Innovus Pharma to Raise USD0.3 Million Private Placement of 5% Notes Due 2016 61
Innovus Pharma to Raise USD0.3 Million Private Placement of 5% Notes Due 2016 62
Innovus Pharma Raises USD0.1 Million in Private Placement of Notes 63
Innovus Pharma Raises USD0.1 Million in Private Placement of 8% Debentures 64
Innovus Pharma Amends Private Placement of 8% Debenture Due 2016 65
Innovus Pharma Raises USD0.3 Million in Private Placement of 10% Debentures due 2015 66
Innovus Pharma Raises USD0.4 Million in Private Placement of 8% Debentures due 2014 67
Innovus Pharma Raises USD0.1 Million in Private Pacement of Convertible Debt 68
Innovus Pharma Raises USD0.2 Million in Private Placement of 8% Debentures 69
Asset Transactions 70
Apricus Biosciences Acquires Remaining 50% Stake Of Rights To PrevOnco From Innovus Pharma 70
Acquisition 71
Innovus Pharma Acquires Novalere 71
Innovus Pharma Acquires Semprae Labs 72
Innovus Pharmaceuticals Inc – Key Competitors 73
Innovus Pharmaceuticals Inc – Key Employees 74
Innovus Pharmaceuticals Inc – Locations And Subsidiaries 75
Head Office 75
Other Locations & Subsidiaries 75
Recent Developments 76
Strategy And Business Planning 76
Oct 16, 2018: Innovus Pharma to expand its Amazon store to Japan 76
Jun 21, 2018: Innovus Pharma Receives Approval from Amazon to Expand its Amazon Stores to Europe Covering the United Kingdom, France, Germany, Spain and Italy 77
Financial Announcements 78
Jul 17, 2018: Innovus Pharmaceuticals Reports Preliminary Q2 2018 Sales Revenue of $6.6 million to $6.8 million 78
May 14, 2018: Innovus Pharmaceuticals announces quarterly revenue for Q1 2018 79
Apr 02, 2018: Innovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 Million to $4.4 Million 80
Nov 14, 2017: Innovus Pharmaceuticals Reports Nine Month Net Revenue of $6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016 81
Aug 14, 2017: Innovus Pharmaceuticals Reports a Quarterly Net Revenue Increase of 99.2% and Net Loss Decrease of 74.1% Compared to the Same Period in 2016 82
May 12, 2017: Innovus Pharmaceuticals Reports Quarterly Revenue for the First Quarter 2017 of $2.2 Million 83
Mar 06, 2017: Innovus Pharmaceuticals Reports Record Annual Revenues for the Full Year 2016 of $4.8 Million 84
Corporate Communications 85
Apr 23, 2018: Innovus Pharma Expands its Senior Management with the Addition of Ryan Selhorn, CPA, as its Vice President, Chief Financial Officer 85
Legal and Regulatory 86
Dec 04, 2017: Innovus Pharma Files Application for the Commercialization of ProstaGorx for Benign Prostatic Hyperplasia (“BPH”) as a Natural Health Product in Canada 86
Oct 18, 2017: Innovus Pharma Receives Approval from Health Canada for Vesele as a Natural Health Product 87
Product News 88
Nov 14, 2017: Innovus Pharma Launches FlutiCare OTC Nasal Spray Allergy Relief in the U.S. 88
Sep 19, 2017: Innovus Pharma Announces the Launch of Zestra in France, Belgium and Monaco by Its Partner, Densmore 89
Jun 01, 2017: Innovus Pharma Announces Positive Pre-Clinical Synergistic Effects of Vesele in Combination with Sildenafil on Nitric Oxide Production 90
May 24, 2017: Innovus Pharma Launches AllerVarx, a Clinically Proven Supplement for the Relief of Allergy Symptoms, in the United States 91
May 01, 2017: Innovus Pharma Launches ProstaGorx Product for Prostate Health Through its Beyond Human Sales and Marketing Platform in the United States 92
Apr 13, 2018: Innovus Pharma Announces Its Direct Launch of Apeaz, a Cream for Arthritis Pain Relief, in Canada 93
Other Significant Developments 94
Jan 18, 2018: Innovus Pharma Announces Official Launch of its Amazon, Walmart, eBay and Wish On-Line Stores with a Combined 116 Product SKUs 94
Aug 09, 2017: Innovus Pharma Orders its First Commercial Batch of 220,000 Units of FlutiCare 96
Apr 05, 2017: Innovus Pharma Announces Receipt of Notification to Commercialize Zestra Glide in the European Union 97
Mar 02, 2017: Innovus Pharma Announces Receipt of Notification to Commercialize Zestra in the European Union 98
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99

List of Tables
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Innovus Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Innovus Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Innovus Pharma Acquires Assets of Beyond Human for USD0.6 Million 17
Innovus Pharma Acquires Vesele from Trophikos 18
Innovus Pharma Amends Acquisition of Rights to Circumserum from Centric Research for up to USD7.5 Million 19
Innovus Pharma To Acquire Prescription Product Portfolio From Prospector Capital Partners II 20
Innovus Pharma Raises US$0.33 Million In Venture Financing 22
Innovus Pharma To Raise US$1.1 Million In Venture Financing 23
Innovus Pharma Enters into Distribution Agreement with Laboratorios Q Pharma 24
Innovus Pharma Enters into Co-Marketing Agreement with DanaLife for Zestra 25
Innovus Pharma Enters Into Co-Promotion Agreement With Consortia Health For EjectDelay 26
Innovus Pharma Enters into License and Distribution Agreement with Lavasta Pharma 27
Corporacion Pharma Solutions Peru Enters into Licensing Agreement with Innovus Pharma 28
Innovus Pharma Plans to Enter into Licensing Agreement with University of Iowa Research Foundation 29
Luminarie Enters into Licensing Agreement with Innovus Pharma 30
Innovus Pharma Expands Licensing Agreement with Densmore for Zestra 31
Innovus Pharma Enters into Licensing Agreement with NTC 32
Innovus Pharma Enters into Licensing Agreement with J&H Co. for Zestra 33
Elis Pharma Enters into Licensing Agreement with Innovus Pharma for Zestra 34
Innovus Pharma Enters into Licensing Agreement with Seipel 35
Innovus Pharma Enters into Licensing Agreement with BroadMed for EjectDelay 36
Bio Task Enters into Licensing Agreement with Innovus Pharma 37
Khandelwal Labs Enters into Licensing Agreement with Innovus Pharma 38
Elis Pharma Enters into Licensing Agreement with Innovus Pharma 39
BroadMed Enters into Licensing Agreement with Innovus Pharma for Sensum+ 40
Innovus Pharma Enters into Licensing Agreement with Tabuk Pharma 41
Innovus Pharma Enters into Licensing Agreement with Sothema Labs 42
Innovus Pharma Enters into Licensing Agreement with Tramorgan for Sensum+ 43
Orimed Pharma Expands Licensing Agreement with Innovus Pharma 44
Innovus Pharma Enters Into Licensing Agreement With Ovation Pharma For EjectDelay 45
Innovus Pharma Enters Into License And Distribution Agreement With Ovation Pharma For Circumserum 46
Acerus Pharma Enters into Licensing and Distribution Agreement with Innovus Pharma 47
Innovus Pharma Raises Funds through Private Placement 48
Innovus Pharma Prices Public Offering of Shares for USD3.9 Million 49
Innovus Pharma Files Registration Statement for Public Offering of Shares and Warrants for up to USD5 Million 50
Innovus Pharma to Raise Funds in Public Offering of Shares 51
Innovus Pharma to Raise USD0.2 Million in Private Placement of Shares upon Exercise of Warrants 52
Innovus Pharma Completes Private Placement Of Shares For US$0.13 Million 53
Innovus Pharma Completes Private Placement Of Shares For US$0.45 Million 54
Innovus Pharma Completes Private Placement Of Shares For US$4.5 Million 55
Innovus Pharma Raises USD0.8 Million in Third and Final Tranche of Private Placement of 10% Notes Due 2017 56
Innovus Pharma Raises Additional USD0.75 Million in Private Placement of 10% Note Due 2017 57
Innovus Pharma Raises USD1.5 Million in Private Placement of 10% Note Due 2017 58
Innovus Pharmaceuticals Raises USD0.024 Million in Debt Offering of 10% Non-Convertible Debentures 59
Innovus Pharma Raises USD0.5 Million in Private Placement of 5% Notes Due 2016 60
Innovus Pharma to Raise USD0.3 Million Private Placement of 5% Notes Due 2016 61
Innovus Pharma to Raise USD0.3 Million Private Placement of 5% Notes Due 2016 62
Innovus Pharma Raises USD0.1 Million in Private Placement of Notes 63
Innovus Pharma Raises USD0.1 Million in Private Placement of 8% Debentures 64
Innovus Pharma Amends Private Placement of 8% Debenture Due 2016 65
Innovus Pharma Raises USD0.3 Million in Private Placement of 10% Debentures due 2015 66
Innovus Pharma Raises USD0.4 Million in Private Placement of 8% Debentures due 2014 67
Innovus Pharma Raises USD0.1 Million in Private Pacement of Convertible Debt 68
Innovus Pharma Raises USD0.2 Million in Private Placement of 8% Debentures 69
Apricus Biosciences Acquires Remaining 50% Stake Of Rights To PrevOnco From Innovus Pharma 70
Innovus Pharma Acquires Novalere 71
Innovus Pharma Acquires Semprae Labs 72
Innovus Pharmaceuticals Inc, Key Competitors 73
Innovus Pharmaceuticals Inc, Key Employees 74
Innovus Pharmaceuticals Inc, Subsidiaries 75

List of Figures
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Innovus Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Innovus Pharmaceuticals Inc (INNV)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • SynergEyes Inc-医療機器分野：企業M&A・提携分析
    Summary SynergEyes Inc (SynergEyes) is a medical device company that offers contact lenses. The company offers hybrid contact lenses to transform vision for patients with astigmatism, presbyopia, presbyopia, myopia, hyperopia, keratoconus, and other eye conditions. It provides ultrahealth hybrid len …
  • Albena AD Albena ：企業の戦略・SWOT・財務情報
    Albena AD Albena - Strategy, SWOT and Corporate Finance Report Summary Albena AD Albena - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Maerki Baumann & Co. AG：企業の戦略・SWOT・財務情報
    Maerki Baumann & Co. AG - Strategy, SWOT and Corporate Finance Report Summary Maerki Baumann & Co. AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Assertio Therapeutics Inc：企業の戦略・SWOT・財務分析
    Assertio Therapeutics Inc - Strategy, SWOT and Corporate Finance Report Summary Assertio Therapeutics Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Source Plc：企業の戦略・SWOT・財務情報
    Source Plc - Strategy, SWOT and Corporate Finance Report Summary Source Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Rezolute Inc (RZLT)：製薬・医療：M&Aディール及び事業提携情報
    Summary Rezolute Inc (Rezolute) formerly known as AntriaBio Inc, is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for the treatment of metabolic and orphan diseases. Its pipeline product portfolio includes AB101, a microsphere formulation of …
  • Pharmsynthez (LIFE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Pharmsynthez is a pharmaceutical company that manufactures and markets generic active pharmaceutical ingredients. The company offers production and sales of both officinal medicines (original OM) and active pharmaceutical ingredients (API). It offers drugs such as vazostenon, glaumax, cathal …
  • HP Inc.：企業の戦略・SWOT・財務情報
    HP Inc. - Strategy, SWOT and Corporate Finance Report Summary HP Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Morneau Shepell Inc.：企業の戦略・SWOT・財務分析
    Morneau Shepell Inc. - Strategy, SWOT and Corporate Finance Report Summary Morneau Shepell Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Hindustan ZInc Ltd：企業の戦略・SWOT・財務分析
    Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report Summary Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Federal Signal Corporation：企業の戦略・SWOT・財務情報
    Federal Signal Corporation - Strategy, SWOT and Corporate Finance Report Summary Federal Signal Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Uelzena eG：企業の戦略・SWOT・財務情報
    Uelzena eG - Strategy, SWOT and Corporate Finance Report Summary Uelzena eG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Moberg Pharma AB (MOB)：製薬・医療：M&Aディール及び事業提携情報
    Summary Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged …
  • Pennon Group Plc：企業の戦略・SWOT・財務情報
    Pennon Group Plc - Strategy, SWOT and Corporate Finance Report Summary Pennon Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Memorial Health System：企業の戦略的SWOT分析
    Memorial Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Alfresa Holdings Corporation：企業の戦略・SWOT・財務情報
    Alfresa Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Alfresa Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Guthy-Renker LLC：企業の戦略的SWOT分析
    Guthy-Renker LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • SciClone Pharmaceuticals Inc：企業の戦略的SWOT分析
    SciClone Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Gulf Oil Limited Partnership：企業の戦略的SWOT分析
    Gulf Oil Limited Partnership - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Aequus Pharmaceuticals Inc (AQS)：企業の財務・戦略的SWOT分析
    Summary Aequus Pharmaceuticals Inc (Aequus Pharmaceuticals) is a drug discovery and development company that develops differentiated drugs. The company’s pipeline products include AQS301, AQS302 and AQS303. Its commercial pipeline comprises ophthalmology products and transplant products. Aequus Phar …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆